Peripheral blood lymphocytes from patients with rheumatoid arthritis are differentially sensitive to apoptosis induced by anti-tumour necrosis factor-alpha therapy

Clinical and Experimental Rheumatology

Volumn 26, Issue 2, 2008, Pages 234-239

  Coury, F ^a   Ferraro Peyret, C ^a   Le Cam, S ^a   Guerin, S ^a   Tebib, J ^a   Sibilia, J ^b   Bienvenu, J ^a   Fabien, Nicole ^a  

^a HOSPICES CIVILS DE LYON   (France)

^b HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

Anti TNF alpha therapies; Apoptosis; Lymphocytes; Rheumatoid arthritis

Indexed keywords

ETANERCEPT; INFLIXIMAB; LIPOCORTIN 5; METHOTREXATE; PHOSPHATIDYLSERINE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGED; APOPTOSIS; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOFLUOROMETRY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; APOPTOSIS; ARTHRITIS, RHEUMATOID; CELLS, CULTURED; FEMALE; HUMANS; IMMUNOGLOBULIN G; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 43349095274     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. MAINI R, ST CLAIR EW, BREEDVELD F et al.: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932-9.
2. WEINBLATT ME, KREMER JM, BANKHURST AD et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253-9.
3. DEN BROEDER A, VAN DE PUTTE L, RAU R et al.: A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol 2002; 29: 2288-98.
4. FIRESTEIN GS, YEO M, ZVAIFLER NJ: Apoptosis in rheumatoid arthritis synovium. J Clin Invest 1995; 96: 1631-8.
5. TAK PPFGS: Apoptosis in rheumatoid arthritis. Apoptosis and Inflammation. Winkler JD (Ed.) 1999; 149-62.
6. BAIER A, MEINECKEL I, GAY S et al.: Apoptosis in rheumatoid arthritis. Curr Opin Rheumatol 2003; 15: 274-9.
7. SALMON M, SCHEEL-TOELLNER D, HUISSOON AP et al.: Inhibition of T cell apoptosis in the rheumatoid synovium. J Clin Invest 1997; 99: 439-46.
8. MAAS K, MHAN S, PARKER J et al.: Cutting edge: molecular portrait of human autoimmune disease. J Immunol 2002; 169: 5-9.
9. TEN HOVE T, VAN MONTFRANS C, PEPPELENBOSCH MP et al.: Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002; 50:206-11.
10. LUGERING A, SCHMIDT M, LUGERING N et al.: Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001; 121: 1145-57.
11. VAN DEN BRANDE JM, BRAAT H, VAN DEN BRINK GR et al.: Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003; 124: 1774-85.
12. DI SABATINO A, CICCOCIOPPO R, CINQUE B et al.: Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Gut 2004; 53: 70-7.
13. MITOMA H, HORIUCHI T, HATTA N et al.: Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology 2005; 128: 376-92.
14. VAN DEVENTER SJ: Transmembrane TNF-alpha, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease. Gastroenterology 2001; 121: 1242-6.
15. TAK PP: Effects of infliximab treatment on rheumatoid synovial tissue. J Rheumatol (Suppl.) 2005; 74: 31-4.
16. CATRINA AI, TROLLMO C, AF KLINT E et al.: Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: Extended report. Arthritis Rheum 2005; 52: 61-72.
17. SMEETS TJ, KRAAN MC, VAN LOON ME et al.: Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum 2003; 48: 2155-62.
18. SHEN C, ASSCHE GV, COLPAERT S et al.: Adalimumab induces apoptosis of human monocytes: A comparative study with infliximab and etanercept. Aliment Pharmacol Ther 2005; 21: 251-8.
19. WATTS AD, HUNT NH, WANIGASEKARA Y et al.: A casein kinase I motif present in the cytoplasmic domain of members of the tumour necrosis factor ligand family is implicated in 'reverse signalling'. Embo J 1999; 18: 2119-26.
20. VIGNA-PEREZ M, ABUD-MENDOZA C, PORTILLO-SALAZAR H et al.: Immune effects of therapy with Adalimumab in patients with rheumatoid arthritis. Clin Exp Immunol 2005; 141: 372-80.
21. BALOG A, KLAUSZ G, GAL J et al.: Investigation of the prognostic value of TNF-alpha gene polymorphism among patients treated with infliximab, and the effects of infliximab therapy on TNF-alpha production and apoptosis. Pathobiology 2004; 71: 274-80.
22. SIGAL LH: Basic science for thH clinician 42: handling the corpses: apoptosis, necrosis, nucleosomes and (quite possibly) the immunopathogenesis of SLE. J Clin Rheumatol 2007; 13: 44-8.
23. EMLEN W, NIEBUR J, KADERA R: Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol 1994; 152: 3685-92.
24. MAINI RN, BREEDVELD FC, KALDEN JR et al.: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552-63.
25. FINCKH A, SIMARD JF, GABAY C et al.: Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis 2006; 65: 746-52.